Compare AENT & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AENT | LCTX |
|---|---|---|
| Founded | 1990 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Durable Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.4M | 366.2M |
| IPO Year | N/A | N/A |
| Metric | AENT | LCTX |
|---|---|---|
| Price | $7.10 | $1.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $10.00 | $4.67 |
| AVG Volume (30 Days) | 61.0K | ★ 1.1M |
| Earning Date | 02-12-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 131.70 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $1,088,441,000.00 | $10,816,000.00 |
| Revenue This Year | $8.23 | $6.32 |
| Revenue Next Year | $2.26 | $124.49 |
| P/E Ratio | $16.49 | ★ N/A |
| Revenue Growth | N/A | ★ 24.05 |
| 52 Week Low | $2.21 | $0.37 |
| 52 Week High | $8.80 | $2.09 |
| Indicator | AENT | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.44 |
| Support Level | N/A | $1.45 |
| Resistance Level | N/A | $1.80 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 65.71 |
Alliance Entertainment Holding Corp is a distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world. The company has two divisions: Alliance Home Entertainment, which offers full-service support across production, marketing, and retail execution. and Alliance Authentic, which focuses on licensed collectibles and branded merchandise, including partnerships with Handmade by Robots, Master Replicas, and Weta Workshop.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.